1. Severe mold fungal infections in critically ill patients with COVID-19.
- Author
-
Koulenti D, Paramythiotou E, Almyroudi MP, Karvouniaris M, Markou N, Paranos P, Routsi C, Meletiadis J, and Blot S
- Subjects
- Humans, Risk Factors, Aspergillus isolation & purification, Aspergillus pathogenicity, Aspergillosis epidemiology, Aspergillosis microbiology, Mucor isolation & purification, Mucor pathogenicity, Antifungal Agents therapeutic use, Incidence, COVID-19 complications, COVID-19 epidemiology, Critical Illness, Mucormycosis epidemiology, Coinfection epidemiology, Coinfection microbiology, Coinfection virology, SARS-CoV-2, Invasive Fungal Infections epidemiology
- Abstract
The SARS-CoV-2 pandemic put an unprecedented strain on modern societies and healthcare systems. A significantly higher incidence of invasive fungal co-infections was noted compared with the pre-COVID-19 era, adding new diagnostic and therapeutic challenges in the critical care setting. In the current narrative review, we focus on invasive mold infections caused by Aspergillus and Mucor species in critically ill COVID-19 patients. We discuss up-to-date information on the incidence, pathogenesis, diagnosis and treatment of these mold-COVID-19 co-infections, as well as recommendations on preventive and prophylactic interventions. Traditional risk factors were often not recognized in COVID-19-associated aspergillosis and mucormycosis, highlighting the role of other determinant risk factors. The associated patient outcomes were worse compared with COVID-19 patients without mold co-infection.
- Published
- 2024
- Full Text
- View/download PDF